Literature DB >> 16897361

Endothelin signaling pathways in rat adrenal medulla.

Israel Anita1, Mathison Yaira, Garrido María del Rosario.   

Abstract

1. We further characterized the effect of endothelins (ETs) on receptor-mediated phosphoinositide (PI) turnover, nitric oxide synthase (NOS) activation, and cGMP formation in whole rat adrenal medulla. 2. The PI hydrolysis was assessed as accumulation of inositol monophosphates (InsP(1)) in the presence of 10 mM LiCl in whole tissue and the analysis of inositol-1-phosphate by Dowex anion exchange chromatography. NOS activity was assayed by monitoring the conversion of radiolabeled L-arginine to L-citrulline. Cyclic GMP formation was assessed as accumulation of cGMP in whole tissue in the presence of phosphodiesterase inhibition, and the amount of cGMP formed was determined by radioimmuno-antibody procedure. 3. ET-1 and ET-3 increased PI turnover by 30% in whole adrenal medulla prelabeled with [(3)H] myoinositol. Both ETs isoforms, at equimolar doses, increased NOS activity and cGMP levels in similar degree. The selective ET(B) receptor agonist, IRL-1620, also increased cGMP formation, mimicking the effects of ETs, while IRL-1620 did not alter the PI metabolism. ETs-induced InsP(1) accumulation and cGMP was dependent on extracellular calcium. The effect of ETs on PI turnover was inhibited by neomycin. The L-arginine analogue, N-nitro-L-arginine (L-NAME), and two inhibitors of soluble guanylyl cyclase, methylene blue and ODQ, significantly inhibited the increase in cGMP production induced by ETs or IRL-1620. The selective ET(A) receptor antagonist, BQ 123, inhibited the ETs-induced increase in PI turnover, while the selective ET(B) receptor antagonist, BQ 788, was ineffective. Likewise, BQ 788, significantly inhibited ET-1- or ET-3-induced NOS activation and cGMP generation but not ETs-induced InsP(1) accumulation. 4. Our data indicate that stimulation of PI turnover and NO-induced cGMP generation constitutes ETs signaling pathways in rat adrenal medulla. The former action is mediated through activation of ET(A) receptor, while the latter through the activation of ET(B) receptor. These results support the role of endothelins in the regulation of adrenal medulla function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16897361     DOI: 10.1007/s10571-006-9111-3

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  70 in total

1.  Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme.

Authors:  D S Bredt; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

2.  Endothelin-induced activation of phosphoinositide turnover, calcium mobilization, and transmitter release in cultured neurons and neurally related cell types.

Authors:  D M Chuang; W W Lin; C Y Lee
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

Review 3.  Endothelins: homeostatic and compensatory actions in the circulatory and endocrine systems.

Authors:  T Masaki
Journal:  Endocr Rev       Date:  1993-06       Impact factor: 19.871

4.  Stimulation of endothelin B receptors in astrocytes induces cAMP response element-binding protein phosphorylation and c-fos expression via multiple mitogen-activated protein kinase signaling pathways.

Authors:  S Schinelli; P Zanassi; M Paolillo; H Wang; A Feliciello; V Gallo
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

5.  Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells.

Authors:  M R Boarder; D B Marriott
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

6.  Sequential and opposite regulation of two outward K(+) currents by ET-1 in cultured striatal astrocytes.

Authors:  R Bychkov; J Glowinski; C Giaume
Journal:  Am J Physiol Cell Physiol       Date:  2001-10       Impact factor: 4.249

7.  Distribution and functional significance of the endothelin receptor subtypes in the rat adrenal gland.

Authors:  A S Belloni; Y G Pacheco; A Markowska; P G Andreis; V Meneghelli; L K Malendowicz; G G Nussdorfer
Journal:  Cell Tissue Res       Date:  1997-05       Impact factor: 5.249

8.  Multiple signaling pathways in bovine chromaffin cells regulate tyrosine hydroxylase phosphorylation at Ser19, Ser31, and Ser40.

Authors:  J W Haycock
Journal:  Neurochem Res       Date:  1993-01       Impact factor: 3.996

9.  Endothelin-1 gene expression in human pheochromocytoma.

Authors:  J A Amico; M R Clarke; C G Watson; N B Kim; P L Bononi; R S Crowley; M J Horwitz
Journal:  J Lab Clin Med       Date:  1993-12

10.  A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta.

Authors:  Y Fujitani; H Ueda; T Okada; Y Urade; H Karaki
Journal:  J Pharmacol Exp Ther       Date:  1993-11       Impact factor: 4.030

View more
  3 in total

Review 1.  Response of substances co-expressed in hypothalamic magnocellular neurons to osmotic challenges in normal and Brattleboro rats.

Authors:  Jana Bundzikova; Zdeno Pirnik; Dora Zelena; Jens D Mikkelsen; Alexander Kiss
Journal:  Cell Mol Neurobiol       Date:  2008-09-05       Impact factor: 5.046

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

3.  SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions.

Authors:  Lei L Chen; Jing Zhu; Jonathan Schumacher; Chongjuan Wei; Latha Ramdas; Victor G Prieto; Arnie Jimenez; Marco A Velasco; Sheryl R Tripp; Robert H I Andtbacka; Launce Gouw; George M Rodgers; Liansheng Zhang; Benjamin K Chan; Pamela B Cassidy; Robert S Benjamin; Sancy A Leachman; Marsha L Frazier
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.